Search Results

There are 1394 results for: content related to: Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

  1. You have full text access to this OnlineOpen article
    CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

    Cancer Medicine

    Volume 4, Issue 5, May 2015, Pages: 661–672, Luis H. Camacho

    Version of Record online : 25 JAN 2015, DOI: 10.1002/cam4.371

  2. You have free access to this content
    Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

    Cancer

    Volume 119, Issue 9, 1 May 2013, Pages: 1675–1682, Jeffrey S. Weber, Reinhard Dummer, Veerle de Pril, Celeste Lebbé, F. Stephen Hodi and for the MDX010-20 Investigators

    Version of Record online : 7 FEB 2013, DOI: 10.1002/cncr.27969

  3. You have full text access to this OnlineOpen article
    Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

    British Journal of Clinical Pharmacology

    Volume 78, Issue 1, July 2014, Pages: 106–117, Yan Feng, Eric Masson, David Dai, Susan M. Parker, David Berman and Amit Roy

    Version of Record online : 20 JUN 2014, DOI: 10.1111/bcp.12323

  4. You have free access to this content
    Checkpoint blocking antibodies in cancer immunotherapy

    FEBS Letters

    Volume 588, Issue 2, January 21, 2014, Pages: 368–376, Chrisann Kyi and Michael A. Postow

    Version of Record online : 23 OCT 2013, DOI: 10.1016/j.febslet.2013.10.015

  5. You have full text access to this OnlineOpen article
    Ipilimumab and radiation therapy for melanoma brain metastases

    Cancer Medicine

    Volume 2, Issue 6, December 2013, Pages: 899–906, Ann W. Silk, Michael F. Bassetti, Brady T. West, Christina I. Tsien and Christopher D. Lao

    Version of Record online : 10 OCT 2013, DOI: 10.1002/cam4.140

  6. You have full text access to this OnlineOpen article
    Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

    Cancer

    Volume 116, Issue 7, 1 April 2010, Pages: 1767–1775, Geoffrey Y. Ku, Jianda Yuan, David B. Page, Sebastian E. A. Schroeder, Katherine S. Panageas, Richard D. Carvajal, Paul B. Chapman, Gary K. Schwartz, James P. Allison and Jedd D. Wolchok

    Version of Record online : 8 FEB 2010, DOI: 10.1002/cncr.24951

  7. You have full text access to this OnlineOpen article
    Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery

    Cancer Medicine

    Volume 4, Issue 1, January 2015, Pages: 1–6, Karim Tazi, Amanda Hathaway, Cody Chiuzan and Keisuke Shirai

    Version of Record online : 27 AUG 2014, DOI: 10.1002/cam4.315

  8. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 35, Issue 10, October 2015, Pages: 963–976, Ninh M. La-Beck, Gary W. Jean, Cindy Huynh, Saeed K. Alzghari and Devin B. Lowe

    Version of Record online : 24 OCT 2015, DOI: 10.1002/phar.1643

    Corrected by:

    Erratum: Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

    Vol. 35, Issue 12, 1205, Version of Record online: 19 DEC 2015

  9. You have full text access to this OnlineOpen article
    Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

    Annals of the New York Academy of Sciences

    Volume 1291, Issue 1, July 2013, Pages: 1–13, Jedd D. Wolchok, F. Stephen Hodi, Jeffrey S. Weber, James P. Allison, Walter J. Urba, Caroline Robert, Steven J. O'Day, Axel Hoos, Rachel Humphrey, David M. Berman, Nils Lonberg and Alan J. Korman

    Version of Record online : 17 JUN 2013, DOI: 10.1111/nyas.12180

  10. You have free access to this content
    Poster

    JDDG: Journal der Deutschen Dermatologischen Gesellschaft

    Volume 13, Issue S2, August 2015, Pages: 20–64,

    Version of Record online : 20 AUG 2015, DOI: 10.1111/ddg.12784

  11. Systematic review: colitis associated with anti-CTLA-4 therapy

    Alimentary Pharmacology & Therapeutics

    Volume 42, Issue 4, August 2015, Pages: 406–417, A. Gupta, K. M. De Felice, E. V. Loftus Jr and S. Khanna

    Version of Record online : 15 JUN 2015, DOI: 10.1111/apt.13281

  12. Inhibitory receptors as targets for cancer immunotherapy

    European Journal of Immunology

    Volume 45, Issue 7, July 2015, Pages: 1892–1905, Meghan E. Turnis, Lawrence P. Andrews and Dario A. A. Vignali

    Version of Record online : 6 JUL 2015, DOI: 10.1002/eji.201344413

  13. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series

    Internal Medicine Journal

    Volume 45, Issue 10, October 2015, Pages: 1066–1073, T. Lam, M. M. K. Chan, A. N. Sweeting, S. M. C. De Sousa, A. Clements, M. S. Carlino, G. V. Long, K. Tonks, E. Chua, R. F. Kefford and D. R Chipps

    Version of Record online : 1 OCT 2015, DOI: 10.1111/imj.12819

    Corrected by:

    Corrigendum: Corrigendum

    Vol. 45, Issue 12, 1318, Version of Record online: 9 DEC 2015

  14. You have free access to this content
    Clinical activity of ipilimumab for metastatic uveal melanoma

    Cancer

    Volume 119, Issue 20, 15 October 2013, Pages: 3687–3695, Jason J. Luke, Margaret K. Callahan, Michael A. Postow, Emanuela Romano, Nikhil Ramaiya, Mark Bluth, Anita Giobbie-Hurder, Donald P. Lawrence, Nageatte Ibrahim, Patrick A. Ott, Keith T. Flaherty, Ryan J. Sullivan, James J. Harding, Sandra D'Angelo, Mark Dickson, Gary K. Schwartz, Paul B. Chapman, Jedd D. Wolchok, F. Stephen Hodi and Richard D. Carvajal

    Version of Record online : 2 AUG 2013, DOI: 10.1002/cncr.28282

  15. You have full text access to this OnlineOpen article
    Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

    Cancer Medicine

    Volume 2, Issue 2, April 2013, Pages: 243–252, Edward Cha and Eric J. Small

    Version of Record online : 24 FEB 2013, DOI: 10.1002/cam4.64

  16. Morphomics predicts response to ipilimumab in patients with stage IV melanoma

    Journal of Surgical Oncology

    Volume 112, Issue 4, September 15, 2015, Pages: 333–337, Michael S. Sabel, Jay Lee, Anran Wang, Christopher Lao, Sven Holcombe and Stewart Wang

    Version of Record online : 7 AUG 2015, DOI: 10.1002/jso.24003

  17. You have free access to this content
    Ipilimumab-induced toxicities and the gastroenterologist

    Journal of Gastroenterology and Hepatology

    Volume 30, Issue 4, April 2015, Pages: 657–666, Robert Cheng, Adam Cooper, James Kench, Geoff Watson, William Bye, Catriona McNeil and Nicholas Shackel

    Version of Record online : 16 MAR 2015, DOI: 10.1111/jgh.12888

  18. Melanoma Treatments: Advances and Mechanisms

    Journal of Cellular Physiology

    Volume 230, Issue 11, November 2015, Pages: 2626–2633, Alexander Marzuka, Laura Huang, Nicholas Theodosakis and Marcus Bosenberg

    Version of Record online : 27 JUL 2015, DOI: 10.1002/jcp.25019

  19. You have free access to this content
    New clinical advances in immunotherapy for the treatment of solid tumours

    Immunology

    Volume 145, Issue 2, June 2015, Pages: 182–201, Valentina A. Zavala and Alexis M. Kalergis

    Version of Record online : 30 MAR 2015, DOI: 10.1111/imm.12459

  20. You have free access to this content
    High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma

    British Journal of Dermatology

    Volume 174, Issue 1, January 2016, Pages: 146–151, J. Zaragoza, A. Caille, N. Beneton, G. Bens, F. Christiann, H. Maillard and L. Machet

    Version of Record online : 25 NOV 2015, DOI: 10.1111/bjd.14155